Compositions comprising a complement inhibitor and an interferon alpha inhibitor

Abstract

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos' disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or to a biologically-active fragment of C5 such as C5a or C5b. In some embodiments, the inhibitor is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or to an interferon alpha receptor.

What is claimed is: 
     
         1 . A composition or package comprising: (i) a complement inhibitor and (ii) an inhibitor of interferon alpha. 
     
     
         2 . The composition of  claim 1 , wherein the complement inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein. 
     
     
         3 . The composition of  claim 2 , wherein the antibody, or antigen binding fragment thereof, inhibits the cleavage of complement component C5 into fragments C5a and C5b. 
     
     
         4 . The composition of  claim 2 , wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a humanized antibody, a recombinant antibody, a diabody, a chimerized or chimeric antibody, a deimmunized human antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab′fragment, and an F(ab′) 2  fragment. 
     
     
         5 . The composition of  claim 1 , wherein the antibody is eculizumab. 
     
     
         6 . The composition of  claim 1 , wherein the antibody is pexelizumab. 
     
     
         7 . The composition of  claim 1 , wherein the inhibitor of interferon alpha is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or an interferon alpha receptor. 
     
     
         8 . The composition of  claim 7 , wherein the antibody, or antigen-binding fragment thereof, that binds to interferon alpha or an interferon alpha receptor is selected from the group consisting of a monoclonal antibody, a humanized antibody, a recombinant antibody, a diabody, a chimerized or chimeric antibody, a deimmunized human antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab′fragment, and an F(ab′) 2  fragment. 
     
     
         9 . The composition of  claim 1 , wherein the composition is formulated for parental administration. 
     
     
         10 . The composition of  claim 1 , further comprising an immunosuppressive agent, an antibiotic or an anti-viral agent. 
     
     
         11 . The composition of  claim 10 , wherein the immunosuppressive agent is selected from the group consisting of corticosteroids, phenylbutazone, azathioprine, methotrexate, cyclosporine, tacrolimus, and mycophenolate mofetil, cyclophosphamide, and an anti-CD20 agent. 
     
     
         12 . The composition of  claim 1 , further comprising a second inhibitor of interferon alpha. 
     
     
         13 . The package of  claim 1 , wherein the complement inhibitor and an inhibitor of interferon alpha are formulated separately. 
     
     
         14 . The package of  claim 1 , wherein the complement inhibitor and an inhibitor of interferon alpha are formulated together.